In one Israeli study, conducted during the BA.1 and BA.2 wave, patients who took Evusheld were half as likely to become infected with Covid, and 92% less likely to 1 be hospitalised or die. Lab-based and real-world evidence show that Evusheld is effective against Omicron BA.1, BA.2, BA.4 and BA.5 (to varying degrees).